Results 91 to 100 of about 32,708 (306)
Movement Disorders Clinical Practice, EarlyView.Abstract Background Leucine‐rich repeat kinase 2 (LRRK2) p.L1795F variant was proposed as a genetic risk factor for Parkinson's disease (PD). However, its prevalence, phenotype, and origin remain unknown. Objective The aim was to evaluate the frequency and phenotype of p.L1795F in early‐onset PD (EOPD) and familial PD compared to healthy controls (HC ...
Miriam Ostrozovicova +35 more
wiley +1 more source
Caring for continence in stroke care settings: a qualitative study of patients’ and staff perspectives on the implementation of a new continence care intervention [PDF]
, 2016 Objectives: Investigate the perspectives of patients and nursing staff on the implementation of an augmented continence care intervention after stroke. Design: Qualitative data were elicited during semi-structured interviews with patients (n = 15) and ...
Brady, MC +6 more
core +2 more sources
International Brazilian Journal of Urology, 2012 Purpose To assess the occurrence and the associated risk factors for nocturia among middle-aged and elderly people from public health centers in southern Taiwan.
Mei-Huang Huang +3 more
doaj +1 more source
Neurourology and Urodynamics, 2020 The prevalence of nocturia in patients with obstructive sleep apnea syndrome (OSAS) who received continuous positive airways pressure (CPAP) treatment was studied as well as the effect of CPAP treatment on nocturia.
O. Vrooman +6 more
semanticscholar +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Levodopa–entacapone–carbidopa intestinal gel (LECIG) was introduced in 2018 as a device‐aided therapy for advanced Parkinson's disease (PD). Objectives The ELEGANCE study (NCT05043103) is gathering real‐world data on long‐term efficacy, safety and patient‐reported outcomes with LECIG from 13 European countries.
Daniel Weiss +10 more
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a well‐established therapy in advanced Parkinson's disease (PD) improving motor and non‐motor signs including sleep. The mechanisms of sleep improvement are insufficiently understood.
Julia Steinhardt +6 more
wiley +1 more source
Botulinum toxin-A for the treatment of overactive bladder: UK contributions [PDF]
, 2013 Background: Botulinum toxin-A (BoNT/A) is now established second-line management for refractory overactivebladder (OAB) and recognised in many incontinence guidelines and pathways.
Dasgupta, P +6 more
core +1 more source
Prevalence of Nocturia in Taiwanese Women Aged 20–59 Years
Taiwanese Journal of Obstetrics & Gynecology, 2007 Objective: To estimate the prevalence of nocturia in Taiwanese women aged 20–59 years. Materials and Methods: A random sample of 4,549 women within the age range was selected by a multistage sampling design.
Ching-Hung Hsieh +4 more
doaj +1 more source
Video Urodynamic Study in Patients with Parkinson's Disease and Multiple System Atrophy
Movement Disorders Clinical Practice, EarlyView.Abstract Background Most studies have analyzed the urodynamic characteristics of patients with Parkinson's disease (PD) and multiple system atrophy (MSA) using conventional urodynamic studies. Objectives This study investigated the urodynamic characteristics of both diseases using video urodynamic study (VUDS).
Hyun Sik Yoon +3 more
wiley +1 more source
A core outcome set for localised prostate cancer effectiveness trials [PDF]
, 2017 Objective: To develop a core outcome set (COS) applicable for effectiveness trials of all interventions for localised prostate cancer. Background: Many treatments exist for localised prostate cancer, although it is unclear which offers the ...
Abel, Paul +41 more
core +1 more source